In Vitro Responsiveness of 417 CFTR Variants to Vanzacaftor/Tezacaftor/Ivacaftor.

Authors

Hermann Bihler, Andrey Sivachenko, Priyanka Bhatt, Ashley Baldwin, Jan Harrington, Violaine Bailey, Alexi Panagiotou, Divesh Patel, Michael J Mulligan, Rachel Valdez Misiolek, Kylie Arnold, Yi Cheng, Kevin Coote, Normand E Allaire, Joshua Conte, Karen S Raraigh, Garry R Cutting, Martin Mense

Published in

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society. Sep 11, 2026. Epub Sep 11, 2026.

Abstract

This study sought to identify additional rare CFTR variants that show improved chloride (Cl⁻) transport in response to the modulator combination vanzacaftor/tezacaftor/ivacaftor (VNZ/TEZ/IVA; VTI). It builds on prior work evaluating 655 variants treated with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA; ETI). The findings may inform people with cystic fibrosis (pwCF) and caregivers pursuing off-label access to modulator therapies when genotype-based eligibility is limited.
Fischer Rat Thyroid (FRT) cells, which do not express endogenous CFTR, were transfected with plasmids encoding wildtype (WT) CFTR or specific CFTR variants. After 24 h under control conditions or treatment with VNZ and TEZ, cells received an acute addition of IVA. CFTR activity was quantified using transepithelial current clamp conductance assays. For each variant, we measured basal forskolin (Fsk)/cAMP-stimulated Cl⁻ transport, potentiation by IVA, and responsiveness to the full VTI combination. CFTR maturation was assessed via Western blot.
We evaluated 417 CFTR variants for VTI responsiveness, including 272 tested for the first time and 145 previously categorized as non-responsive (NR) or borderline-responsive (BR) to ETI. Overall, ∼76% of variants achieved ≥10% of WT improvement, the threshold for responsiveness. This included 87% of newly tested variants and 55% of ETI NR/BR variants. Notably, 50 variants classified as NR/BR to ETI reached the responsive threshold with VTI using empirical Bayes criteria. Compared with ETI, VTI demonstrated broader efficacy across this dataset. These results expand the number of CFTR variants likely to benefit from highly effective modulator therapy and highlight remaining variants that may require alternative therapeutic strategies.

PMID:
42728175
Bibliographic data and abstract were imported from PubMed on 12 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.